Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090890 | 0.88 | RBP4 (0.37) | GPR119SSTR4 | |
| SCHEMBL2675436 | 0.86 | GPR119 (0.45) | GPR119 | |
| SCHEMBL10090887 | 0.84 | SLC6A2 (0.40) | GPR119SSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2675452 | 0.75 | GPR119 (0.41) | GPR119 | |
| SCHEMBL10090902 | 0.73 | SSTR4 (0.37) | GPR119SSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL586621 | 0.71 | SLC6A2 (0.45) | GPR119SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10090874 | 0.70 | SLC6A2 (0.41) | GPR119SSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL590425 | 0.70 | SLC6A2 (0.41) | GPR119SSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL590981 | 0.70 | SLC6A2 (0.55) | GPR119SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14668821 | 0.70 | GPR119 (0.56) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173821-B2 | Serotonin and norepinephrine reuptake inhibitor | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, TPH1 | GPR119 708/4885SSTR4 339/4885CHRM4 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.